2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women ...

Viral diseases are still one of the biggest challenges to medical science. Thanks to thousands of years of co-evolution with humans, their ability to harness the biology of their human hosts to survive and thrive makes them very difficult to target with medical treatment. Scientists at the University of North Carolina at Chapel Hill, working ...

Two recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments. In a study published in Cancer Cell led by Kyle Furge, Ph.D. and Aikseng Ooi, Ph.D., researchers provide a more complete understanding of the ...

Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. ...

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation’s top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers – leukemia, lymphoma and multiple myeloma — during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego. Research highlights ...